Yuta Lee, CEO

April 13 | 1:30pm | Dark Horse Consulting Ballroom 

Philadelphia, PA

(Private)

Accelerated Biosciences discovered and has freedom-to-operate to the Human Trophoblast Stem Cell (hTSCs) platform for allogeneic therapies and bioproduction. The biggest challenge in regenerative medicine today is the availability of a clean and well-documented starting cell source. We can differentiate hTSCs into NK, neuronal, pancreatic, hepatic, and kidney cells as well as iPSCs. The iPSC RUO cells are available now. The hTSC GMP will be available in Q2 of 2023 for partnering and licensing opportunities.

www.acceleratedbio.com

Kim Nguyen, Ph.D., Chief Technical Officer

April 12 | 2:00pm | Dark Horse Consulting Ballroom 

Boston, MA

(Private)

Affini-T is unlocking the power of T cells and targeting core oncogenic drivers to develop potentially curative therapies for solid tumor cancers. Our differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last.

www.affinittx.com

Jong Sang Ryu, Ph.D., CEO and Chief Security Officer

April 12 | 10:45am | Dark Horse Consulting Ballroom 

Gimhae, South Korea

(Private)

AffyXell Therapeutics is a joint venture between Daewoong Pharmaceutical and Avacta Group, developing a novel cell and gene therapy to tackle diseases that come from the imbalance of immune system homeostasis. AffyXell’s platform (also known as AFX) was created by converging two proprietary technologies of its parent companies – Daewoong’s mesenchymal stem cell (MSC) and Avacta’s Affimer® platform. The immunomodulation function by MSC is further increased with the Affimer®, and the treatment developed by the AFX platform enhances restoring immunologic balance. AffyXell is developing pipelines taking this new therapeutic approach to lead in resolving fundamental causes of intractable diseases like immune rejection and autoimmune diseases.

www.affyxell.com

Matt Krusen, Senior Account Manager

April 13 | 9:15am | Dark Horse Consulting Ballroom 

Fargo, ND

(NASDAQ: DHR)

Aldevron serves the biotechnology industry with custom production of nucleic acids and proteins. Thousands of clients rely on Aldevron-produced plasmid DNA, RNA, gene editing enzymes, and more for projects ranging from discovery research to clinical trials to commercial applications. These efforts help accelerate the development of treatments for diseases such as cancer, infectious disease, pediatric disorders, and rare diseases. Aldevron specializes in cGMP manufacturing and is known for inventing the GMP-Source® quality system. Aldevron operates the world’s largest cGMP plasmid DNA manufacturing facility, located at company headquarters in Fargo, North Dakota, with additional production facilities in Madison, Wisconsin, and Lincoln, Nebraska.

www.aldevron.com

William Fountain, Head of Analytical Development 

April 12 | 3:00pm | Dark Horse Consulting Ballroom 

Columbus, OH

(Private)

Andelyn Biosciences is a gene therapy CDMO Pioneering Solutions That Turn Hope into Reality™. With 20+ years of experience manufacturing gene therapies, Andelyn’s scientific expertise for development and characterization has led to GMP material being produced for over 75+ worldwide clinical trials and 400+ cGMP clinical batches. Advanced quality systems, full regulatory support, and supply chain vertical integration including GMP plasmids help accelerate the development and manufacturing of innovative therapies to bring more treatments to more patients.

www.andelynbio.com

Brian McGee, Chief Business Officer

April 13 | 11:30am | Dark Horse Consulting Ballroom 

Södertälje, Sweden

(Private)

Anocca uses precision functional analytical biology, industrialized biotechnologies, and advanced software solutions to develop transformative TCR-T cell immunotherapies to treat cancer and other serious diseases. The company has pioneered a scalable proprietary technology platform that authentically, robustly, and precisely recreates T cell immunity. Anocca’s platform enables a deep understanding of disease specific T cell biology and delivers highly targeted cell-based therapies. Anocca has a fully integrated R&D infrastructure that is complemented by an in-house clinical manufacturing and process development facility. Anocca has focused efforts on generating a broad library of high value assets across distinct oncology franchises. The most advanced programs, expected to enter clinical development in 2024, are targeting solid tumors expressing the KRAS-family of driver mutations. Anocca is led by an experienced management team and has raised over 100 million USD from a small, committed group of leading Nordic investors.

www.anocca.com

Sven Kili, M.D., CEO

April 13 | 11:15am | Dark Horse Consulting Ballroom 

Geneva, Switzerland

(Private)

Antion Biosciences is the world leader in efficient, safe, and cost-effective cell multiplex engineering technologies for almost any cell type. We develop cutting-edge allogeneic cell therapies in indications of high unmet medical and technical engineering need for patients who need hope to become reality.

www.antionbio.com

Devyn Smith, Ph.D., CEO

April 12 | 11:45am | Dark Horse Consulting Ballroom 

Cambridge, MA

(Private)

Arbor Biotechnologies is a next-generation gene editing company focused on discovering and developing potentially curative genomic medicines. Founded by Feng Zhang, David Walt, David Scott, and Winston Yan, our proprietary discovery engine is focused on discovering genetic editing capabilities spanning knockdowns to whole gene insertions, which has enabled us to generate the most extensive toolbox of proprietary genomic editors in the industry to date. Leveraging our wholly owned nucleases as the chassis for genetic modification, we can work backward from disease pathology to choose the optimal editing approach that specifically addresses the underlying cause of disease, resulting in a potentially curative medicine for a wider range of genetic disorders. As Arbor continues to advance its pipeline toward the clinic with an initial focus in liver and CNS disease, the company has also secured several partnerships around gene editing and ex vivo cell therapy programs to broaden the reach of its novel nuclease technology.

www.arbor.bio

Tamer Mohamed, Founder and CEO

April 12 | 12:00pm | Dark Horse Consulting Ballroom 

Vancouver, Canada

(Private)

Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat disease. Aspect is applying its full-stack tissue therapeutic platform, including proprietary microfluidic 3D bioprinting technology, computational design, therapeutic cells, and materials science, to create a pipeline of allogeneic bioprinted tissues that replace or repair damaged organ functions. These tissue therapeutics are rationally engineered to be biologically functional, immune-protective, and suitable for surgical implantation.

www.aspectbiosystems.com

Stephane Degove, CEO

April 13 | 4:00pm | Dark Horse Consulting Ballroom 

Evry, France

(Private)

Atamyo Therapeutics is a clinical-stage biopharma focused on the development of a new generation of effective and safe gene therapies for neuromuscular diseases. A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon. Atamyo’s most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage programs targeting respectively LGMD-R9 and LGMD-R5. The name of the company is derived from two words: Celtic Atao which means “Always” or “Forever” and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments.

www.atamyo.com

Brent Rice, Chief Commercial Officer

April 12 | 11:00am | BioCentriq Ballroom 

London, United Kingdom

(NASDAQ GS: AUTL)

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled, and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms, and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.

www.autolus.com

Justin McCue, Ph.D., Chief Technology Officer

April 12 | 2:45pm | Dark Horse Consulting Ballroom 

Kildare, Ireland

(Private)

Avectas is a cell engineering company that has pioneered – SOLUPORE® – a proprietary simple, highly effective automated transfection system to enable efficient and safe genetic modification, accelerating the manufacture of cells for the next generation of cell therapies. The company is partnering its cGMP aligned SOLUPORE® clinical-grade system with cell therapy companies to address emerging cell delivery challenges associated with multiple cell modifications, and engineering of cells that are limited or fragile. SOLUPORE® has strong intellectual property protection through granted and pending patents, including in the U.S. and Europe. Avectas is a private, international company with research facilities in Dublin, as well as an office in Cambridge, MA in the U.S. It has over 30 employees and is led by a team of highly experienced pharmaceutical executives who are supported by a world-class Scientific Advisory Board of cancer cell therapy experts. The company has raised over $40 million USD to date.

www.avectas.com

Lisa Deschamps, CEO

April 13 | 2:00pm | Dark Horse Consulting Ballroom 

London, United Kingdom

(Private)

AviadoBio’s mission is to develop and deliver potentially transformative gene therapies for people living with devastating neurodegenerative diseases such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). With our deep understanding of the brain and suite of proprietary gene therapy platforms and delivery technologies, we are working relentlessly to overcome the challenges of delivering the right drug to the right place. Our innovative, neuroanatomy-led approach is designed to maximize the therapeutic potential of gene therapy to halt or potentially reverse neurodegenerative diseases. AviadoBio has developed a next-generation AAV gene therapy platform focused on controlling gene expression and is complemented by a suite of unique delivery solutions to deliver gene therapies directly to the brain and spinal cord. Our rich heritage in academia complemented by a strong leadership team with extensive gene therapy development and commercialization experience uniquely positions AviadoBio for success in bringing transformative medicines to patients.

www.aviadobio.com

Steven Nichtberger, M.D., President and CEO

April 12 | 12:15pm | BioCentriq Ballroom 

Philadelphia, PA

(NASDAQ: CABA)

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform – encompassing chimeric antigen receptor T cells for autoimmunity (CARTA: CABA-201, a 4-1BB-containing CD19-CAR T) and Cabaletta Bio’s proprietary chimeric autoantibody receptor T cells (CAART: multiple candidates including DSG3-CAART for mucosal pemphigus vulgaris, MuSK-CAART for MuSK myasthenia gravis) – provides multiple opportunities to treat a broad range of autoimmune diseases.

www.cabalettabio.com

Tom Wilton, Chief Business Officer

April 13 | 10:45am | Dark Horse Consulting Ballroom 

Philadelphia, PA

(Private)

Carisma Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors.

www.carismatx.com

Andy Holt, Chief Commercial Officer

April 13 | 10:30am | Dark Horse Consulting Ballroom 

Charleroi, Belgium

(Private)

Launched in April 2022, Cellistic specializes in process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. Our focus and expertise in iPSC reprogramming, differentiation, and expansion protocol development position us to be the partner of choice for innovative cell therapy developers to commercialize novel advanced therapies. Leveraging more than a decade of Ncardia’s scientific and technical iPSC knowledge and experience, Cellistic possesses unique capabilities for the design and optimization of proprietary manufacturing platforms for iPSC-based cells that deliver quality products at scale.

www.cellistic.com

Rodolphe Clerval, CEO

April 13 | 1:30pm | BioCentriq Ballroom 

Paris, France

(Private)

Coave Therapeutics is a genetic medicine company leading the transition of gene therapy from (ultra) rare to prevalent conditions, with an initial focus on neurodegenerative diseases. Coave’s proprietary ALIGATER™ (AAV-Ligand Conjugate) platform introduces chemical modifications to AAV capsids, overcoming the limitations of current vectors on efficacy, safety, and manufacturability. With low doses and optimized routes of administration, our conjugated AAV vectors have demonstrated markedly improved transduction and biodistribution in the central nervous system and the eye across different species. Coave develops a diversified pipeline of novel genetic medicines that can potentially transform the lives of people afflicted by rare and prevalent neurodegenerative and ocular diseases – including genetically (GBA1-Parkinson, PDE6b-IRD) and non-genetically defined indications (MSA, ALS). Coave Therapeutics is backed by leading international life sciences investors.

www.coavetx.com

Ludwig Camusot, Vice President, Global Cryopreservation Strategy

April 12 | 9:15am | Dark Horse Consulting Ballroom 

Brentwood, TN

(NASDAQ: CYRX)

Cryoport Systems is a market leader in globally integrated temperature-controlled supply chain support for critical, irreplaceable products and materials in the life sciences industry. We are already trusted to support over 600 active clinical trials and leading commercial products worldwide – delivering unparalleled, integrated supply chain services for products, therapies, and treatments requiring unique, specialized temperature-controlled management. And, as the life sciences constantly evolve and advance, so do we.

www.cryoport.com

Timothy Schroeder, Chairman and CEO

April 13 | 10:00am | Dark Horse Consulting Ballroom 

Covington, KY

(Private)

CTI is a global research service provider delivering a full suite of services to the pharma and biotech industry. Offering manufacturing, regulatory development and strategy, clinical operations, research site, laboratory, and real-world evidence services, CTI is the only global research service provider with a history of success in regenerative medicine spanning decades, and the ability to support cell and gene therapy programs throughout the entire clinical development lifecycle.

www.ctifacts.com

Ross Macdonald, Ph.D., CEO

April 13 | 12:00pm | BioCentriq Ballroom 

Melbourne, Australia

(ASX:CYP)

Cynata Therapeutics is a clinical-stage stem cell and regenerative medicine company developing a therapeutic mesenchymal stem cell (MSC) platform technology, Cymerus™, utilizing induced pluripotent stem cells (iPSCs) as starting material. Cynata is the global leader in developing iPSC-derived cell therapies. A successful clinical trial in GvHD has been completed, meeting all safety and efficacy endpoints. The company is undertaking a Phase III clinical trial in osteoarthritis with further clinical trials underway in diabetic foot ulcers and expected to commence in 2023 in renal transplantation and in GvHD (following IND clearance from the U.S. FDA in 2022). The Cymerus technology addresses a critical shortcoming in conventional methods of production of MSCs for therapeutic use, which is the ability to achieve consistent, economic manufacture at commercial scale. Cymerus utilizes a proprietary process that is independent of donor limitations providing an off-the-shelf production platform for therapeutic product manufacture.

www.cynata.com

Yvette Leung, Vice President, Head of Corporate Development

April 13 | 2:15pm | Dark Horse Consulting Ballroom 

Watertown, MA

(Private)

Dyno Therapeutics is a pioneer in applying artificial intelligence (AI) and quantitative in vivo experiments to gene therapy. The company’s proprietary CapsidMap™ platform rapidly discovers and systematically optimizes Adeno-Associated Virus (AAV) capsid vectors that significantly outperform current approaches for in vivo gene delivery, thereby expanding the range of diseases treatable with gene therapies. Dyno was founded in 2018 by experienced biotech entrepreneurs and leading scientists in the fields of gene therapy and machine learning.

www.dynotx.com

Philippe Chambon, M.D., Ph.D., CEO

April 13 | 9:30am | Dark Horse Consulting Ballroom 

Paris, France

(Private)

EG 427 develops next-generation gene therapies specifically targeted to underlying mechanism of action, at the local level, in order to address major chronic diseases where it matters and in a safe and cost-effective manner. Non-replicative Herpes Simplex Virus 1 (nrHSV-1) derived vectors are a powerful tool to achieve highly selective, safe, and durable expression of transgenes addressing localized diseases in the peripheral nervous system and beyond.

www.eg427.com

Clare Murray, Ph.D., Senior Vice President, Corporate

April 13 | 11:45am | Dark Horse Consulting Ballroom 

Waltham, MA

(Private)

ElevateBio is a technology-driven company built to power the development of transformative cell and gene therapies today and for many decades to come. The company has industry-leading talent, state-of-the-art facilities, and diverse technology platforms, including gene editing, iPSCs, and protein, vector, and cellular engineering, necessary to drive innovation and commercialization of cellular and genetic medicines. In addition, BaseCamp in Waltham, MA, is a purpose-built facility offering process innovation, process sciences, and cGMP manufacturing. It can support diverse cell and gene therapy products, including autologous, allogeneic, and regenerative medicine cell products and viral vector manufacturing capabilities. Through BaseCamp and its enabling technologies, ElevateBio is growing its collaborations with partners and developing its own portfolio of cellular and genetic medicines. ElevateBio’s team of scientists, drug developers, and company builders are redefining what it means to be a technology company in the world of drug development, blurring the line between technology and healthcare.

www.elevate.bio

Rachel Diamant, Chief Business Officer

April 13 | 12:15pm | Dark Horse Consulting Ballroom 

New York, NY

(Private)

Emendo Biotherapeutics is a next-generation gene editing company with a therapeutic pipeline based on proprietary nucleases. Our nuclease technology combines a discovery pipeline and protein-engineering capabilities, supported by extensive computational and machine learning tools. The resulting panel of novel nucleases is the OMNI series. OMNI nucleases overcome key challenges in the field as they are variable in size and compatible with all delivery modalities (including AAV), diverse PAM recognition allows for 86% genome coverage. Furthermore, the OMNI nucleases are engineered to be hyper-active and super specific thus eliminating off-target effects and enabling allele specific editing. OMNI-A1, an allele specific editor, is at the base of our lead program for ELANE-dependent Severe Congenital Neutropenia (SCN), a dominant negative genetic disease. The therapeutic approach to Familial hypercholesterolemia (FH) utilizes OMNI-A2 to upregulate the expression of the LDLR gene. Additional OMNI nucleases are used for ophthalmology and immune-oncology advanced preclinical-stage programs.

www.emendobio.com

John Maslowski, Chief Commercial Officer

April 12 | 1:45pm | Dark Horse Consulting Ballroom 

Grove City, OH

(Private)

Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutic development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge’s 200,000 square foot facility utilizes 20 cGMP suites in Columbus, Ohio, the Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility focused on AAV manufacturing and can host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most.

www.forgebiologics.com

Mark Swendsen, Chief Revenue Officer 

April 12 | 12:15pm | Dark Horse Consulting Ballroom 

Austin, TX 

(Private) 

Form Bio empowers scientists to accelerate their most important discoveries. Form is an end-to-end computational platform that allows scientists streamline their everyday bioinformatics work. On top of that platform we layer advanced AI-based solutions, focused on specific, complex problems – all aimed at reducing the time and cost needed to get to market. With the most accessible, comprehensive and collaborative platform in the field, Form empowers scientists to efficiently and effectively harness the proliferation of data and computing power that has transformed the science of discovery. Form offers integration of the discovery process with intuitive and easy-to-use software applications, combined with an open and adaptable collaborative environment. Form was developed within Colossal Biosciences and co-founded by Ben Lamm, Andrew Busey, and Kent Wakeford. 

www.formbio.com 

Imen Mestiri, Ph.D., Business Development Officer 

April 13 | 12:15pm | BioCentriq Ballroom 

Évry, France

(Private)

Genethon has been pioneering gene therapy for 30 years. Genethon’s teams have originated multiple gene therapy successes that are now bringing tremendous benefits for patients. Dedicated to tackling rare diseases, Genethon has accumulated world-class expertise in the identification of gene targets, product design, and manufacturing as well as preclinical and clinical development of gene therapies. With 200+ scientists and professionals, Genethon is pursuing its mission to bring life-changing therapies to patients suffering from rare genetic diseases and eradicate these pathologies. Genethon is a not-for-profit organization, created in 1990 by the French Muscular Dystrophy Association (AFM-Telethon).

www.genethon.com

Kate Rochlin, Chief Operating Officer

April 12 | 10:45am | BioCentriq Ballroom 

New York, NY

(NASDAQ: INAB)

IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancer. Our platform employs allogeneic, autologous, iPSCs, and genetically modified approaches to develop novel cell therapies, which are designed to effectively identify and eradicate tumor cells. We are one of the most advanced gamma-delta T cell companies and the first to bring genetically modified gamma-delta T cells into the clinic. Our lead product candidates are currently in Phase I clinical trials: INB-200, for the treatment of newly diagnosed glioblastoma, or GBM, and INB-100, for the treatment of patients with leukemia that are undergoing hematopoietic stem cell transplantation, or HSCT. Our platform has yielded a broad portfolio of preclinical and discovery-stage programs, focused on addressing solid tumors.

www.in8bio.com

Miguel Forte, M.D., Ph.D., CEO and Founder

April 12 | 11:00am | Dark Horse Consulting Ballroom   

Paris, France

(Private)

Developing gene engineered Mesenchymal Stromal Cells for increased therapeutic efficiency in autoimmune diseases.

www.kiji-tx.com

Vasu Rangadass, Ph.D., CEO and President

April 12 | 4:00pm | Dark Horse Consulting Ballroom 

Austin, TX

(Private)

L7 Informatics reimagines data intelligence for modern life sciences and healthcare organizations, optimizing the flow of information between processes and people, unlocking innovation at every stage of the clinical, research, and manufacturing value chains. Our comprehensive operating environment and software stack bring flexible, secure, and collaborative data+intelligence to life sciences organizations. Our end-to-end transformation engine helps solve today’s challenges and realize tomorrow’s opportunities.

www.l7informatics.com

Clare Murray, Ph.D., Senior Vice President, Corporate Development and Operations

April 13 | 2:30pm | Dark Horse Consulting Ballroom 

Durham, NC

(Private)

Life Edit Therapeutics, an ElevateBio company, has a mission to deliver any edit, anywhere to pave the way to faster and safer gene editing therapeutics that cure disease and improve patient lives. We have developed a gene editing platform with unique RNA-guided nucleases (RGNs), base editors, and next-gen editing capabilities which we have validated both ex vivo in a number of relevant cell types, and in vivo in liver and CNS. Life Edit is developing a pipeline of ex vivo edited cell therapies and in vivo gene editing therapies, both wholly owned and through partnerships.

www.lifeeditinc.com

Jeff Liter, President and CEO

April 13 | 11:00am | Dark Horse Consulting Ballroom 

Minneapolis, MN

(Private)

Luminary is a clinical-stage CAR-T therapy company with a novel allogeneic manufacturing platform where our CAR and TCR development utilizes gamma delta cells. What makes our allogeneic therapeutics unique are that our final drug product includes the combinatory power of both the Vẟ1 and Vẟ2 gamma delta cells, giving our therapies the power of both innate and adaptive cancer clearing power. We have multiple solid tumor targets under development with a proprietary signaling method to ensure T cell persistence. Additionally, our Ligand BAFF CAR for hematologic cancers is designed with three antigen receptors specifically designed to overcome antigen escape.

www.luminarytx.com

Sarah Meeks, Ph.D., Senior Vice President, Business Development

April 13 | 1:45pm | Dark Horse Consulting Ballroom 

Rockville, MD

(NASDAQ: MXCT)

MaxCyte is a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development, and commercialization. Over the past twenty years, we have developed and commercialized our proprietary Flow Electroporation platform, which facilitates complex engineering of a wide variety of cells. At MaxCyte, we take a collaborative partnering approach with our clients with the goal of rapidly driving our partners’ development efforts forward through to commercial use, more cost-effectively and with lowered risk. Our broad intellectual property (IP) portfolio, along with our regulatory certifications and support, offer our partners both enhanced IP protection and freedom to operate.

www.maxcyte.com

Anil Narasimha, Ph.D., CEO

April 13 | 4:45pm | Dark Horse Consulting Ballroom   

Oct. 11 | 11:30am | UBC Ballroom 

San Francisco, CA 

(Private) 

Mekonos is a CGT platform company building the future of cell therapies on a chip.  The company’s System on a Chip merges innovations in MEMS, microfluidics, and chemistry for controlled and individualized molecular delivery in cells at scale, offering an integrated solution for advanced cell and gene therapy development from R&D through Manufacturing. Mekonos’ ex vivo delivery technology uses silicon nanoneedles to enable high efficiency cargo delivery into any cell type, including primary immune cells, iPSCs and HSCs.  The company’s nanoneedle-based delivery system — one needle, one cell — offers single-cell precision at scale and a level of consistency unachievable with conventional delivery technologies. The Mekonos platform enables unique cell engineering capabilities, including nuclear delivery, multiplexing and dose control for hyper-precise ex-vivo delivery.

www.mekonos.com 

Jeff Ross, Ph.D., CEO

April 13 | 3:30pm | BioCentriq Ballroom 

Eden Prairie, MN

(NASDAQ: MIRO)

Miromatrix Medical is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients’ lives. The company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The company’s initial development focus is on human livers and kidneys.

www.miromatrix.com

Sean Kevlahan, Ph.D., CEO

April 13 | 2:45pm | Dark Horse Consulting Ballroom 

Boston, MA

(Private)

Nanite is a AI/ML driven biotechnology company developing next-generation non-viral delivery vehicles for gene therapies. At Nanite, we have a broad clinical pipeline with a critical focus on indications with delivery challenges. Our mission is to deliver the undeliverable.

www.nanitebio.com

Raphael Ognar, Co-Founder and CEO

April 12 | 2:15pm | Dark Horse Consulting Ballroom 

Springfield, NJ

(Private)

NKILT Therapeutics is a new cell therapy biotech developing a novel approach of engineering Natural Killer (NK) cells, and other immune cells, to directly target leukemias and solid tumors. In vitro PoC has been confirmed. Our initial platform is based on a novel Chimeric ILT-Receptor (CIR), featuring a unique proprietary binding technology, targeting the inducible immune checkpoint, HLA-G (expressed in over 50% of human cancers). Our initial armored CIR-NK cells will be able to exquisitely target and directly kill cancer cells, but will also activate innate immunity and directly target the tumor’s defense mechanisms. The first indication will be Acute Myeloid Leukemia (AML) as a preclinical and clinical proof of concept, expanding rapidly our core focus in a large array of solid tumors such as Renal Cell Carcinoma (RCC), Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) and more HLA-G+ tumors.

www.nkilt.com

David Main, President and CEO

April 12 | 2:30pm | Dark Horse Consulting Ballroom 

Vancouver, Canada

(Private)

Notch is developing renewable, induced pluripotent stem cell (iPSC)-derived immunotherapies, initially targeting cancer, where cell therapies offer transformational benefits over existing standards of care. Driven to enhance patient outcomes, we are working to maximize the benefit of cell therapies through a proprietary T cell-production platform that combines sophisticated product design with commercially compatible processes. Our platform allows for precision control of notch signaling, which removes several critical limiting factors in the development of cell therapies and delivers the ability to design and manufacture a uniform and unlimited supply of therapeutic T cells. Located in three cell-therapy centers of excellence in Vancouver, Toronto, and Seattle, our team comprises some of the best minds in preclinical science, advanced cell manufacturing, bioengineering, and systems biology.

www.notchtx.com

Salka E Rasmussen, Ph.D., Vice President, Head of Cell Therapy Inovation, Partnerships and Early Portfolio, Cell Therapy R&D

April 13 | 11:45am | BioCentriq Ballroom 

Bagsværd, Denmark

(NOVO-B.CO)

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. For almost 100 years, we have been translating the unmet medical needs of people living with a serious chronic disease into innovative medicines and delivery systems. At Novo Nordisk, we are working to drive change to defeat diabetes and other serious chronic diseases. Our commitment to the research and development of cell therapies has the potential to realize that ambition over time, with our portfolio of emerging cell therapy programs. We are accelerating the research and development processes through global partnerships with world-leading experts and biotech companies, allowing us to deliver transformative cell therapies faster. Our organization spans the entire value chain from R&D to commercialization. This provides us with unique capabilities to research new cell therapies, accelerate clinical development, and manufacture within our own GMP facilities to ensure control over quality.

www.novonordisk.com

Robin Kenselaar, Senior Vice President and General Manager, EMEA

April 12 | 12:00pm | BioCentriq Ballroom 

London, United Kingdom

(NASDAQ: ORTX)

At Orchard Therapeutics, our vision is to end the devastation caused by genetic and other severe diseases. We aim to do this by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease in a single treatment. In 2018, the company acquired GSK’s rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Today, Orchard is advancing a pipeline spanning preclinical, clinical, and commercial stage HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist.

www.orchard-tx.com

Eric Halioua, President and CEO

April 13 | 3:45pm | Dark Horse Consulting Ballroom 

Liège, Belgium

(Private)

Founded in 2014, PDC*line Pharma is a clinical-stage biotech company that develops an innovative class of cancer vaccines, based on a GMP-grade allogeneic therapeutic cell line of Plasmacytoid Dendritic Cells. PDC*line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T cells and is synergistic with checkpoint inhibitors. The technology can be applied to any type of cancer. PDC*line Pharma focuses on the development of PDC*lung01, a candidate for Non-Small-Cell Lung Cancer (NSCLC) currently in phase I/II trials, and PDC*neo with neoantigens in preclinical. The company has a staff of 32, with an experienced management team. It has raised more than €52 million in equity and non-dilutive funding. PDC*line Pharma granted an exclusive license to the LG Chem Life Sciences company in Asian countries, for the development and commercialization of the PDC*lung01. The deal is worth €108 million, plus tiered royalties on net sales.

www.pdc-line-pharma.com

Dirk Hondmann, Ph.D., CEO

April 12 | 4:15pm | Dark Horse Consulting Ballroom 

Boston, MA

(Private)

PeterBio has unique expertise in developing Zinc Finger (ZF) arrays and effector domains for gene editing and gene repression. ZF constructs are small and avoid immune reactions, offering important therapeutic benefits, including repeat dosing when used in combination with a non-viral delivery system. PeterBio has developed two technology platforms: RITDM: an effective and versatile cleavage-free gene editing technology, and T-LOCK: an effective gene repression technology able to target any gene at the transcription level. Our unique benefits, especially for in-vivo applications that are difficult to replicate by existing state-of-the art technologies include: a strong safety profile; ability for repeat dosing; multiple non-viral delivery options; and small size.

www.peterbio.com

Steven Yatomi-Clarke, CEO

April 12 | 11:15am | BioCentriq Ballroom 

Melbourne, Australia

(NASDAQ: PTX)

Prescient has two cell therapy platforms. OmniCAR is a modular, universal immune receptor platform decoupling immune cells from antigen binders. OmniCAR is based on technology licensed from Penn and Oxford. Antigen binders can be administered separately to cells, creating controllable cytotoxicity post infusion. OmniCAR enables multiple antigens to be targeted simultaneously or sequentially, with a single cell product. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. It shifts T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumors. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome suppressive TME. It significantly decreases Tregs; increases expansion of CAR-T cells in vivo; and increases tumor penetration of CAR-T cells. CellPryme-A improves tumor killing and host survival of CAR-T cell therapies, and these benefits are even greater when used in conjunction with CellPryme-M.

www.ptxtherapeutics.com

Peter Francis, M.D., Ph.D., Chief Scientific and Medical Officer

April 12 | 9:30am | Dark Horse Consulting Ballroom 

San Francisco, CA

(Private)

Ray Therapeutics (RayTx) is a late-stage preclinical Bay Area biotechnology company pioneering the first-to-market precision optogenetic therapy for vision restoration that is highly active in ambient lighting and will not require light-enhancing goggles. Our studies have shown for the first time that our proprietary ChRown optogenetic protein can restore high levels of visual acuity, contrast sensitivity, and visual field. Our lead asset, RTx-015, is expected to address the huge unmet medical in people suffering from many forms of retinal blindness (independent of the underlying genetic cause), including those with advanced age-related macular degeneration. RayTx has partnered with a world leading AAV gene therapy manufacturer and is utilizing their proprietary commercial manufacturing process and analytics to maximally de-risk clinical development. RayTx anticipates clinical trials will begin by the end of 2023 in our initial indication, retinitis pigmentosa.

www.raytherapeutics.com

Edward Hodgkin, Ph.D., CEO

April 12 | 11:30am | Dark Horse Consulting Ballroom 

London, United Kingdom

(Private)

Resolution Therapeutics is a biotechnology company developing macrophage cell therapy to treat inflammatory organ disease. Our initial focus is chronic liver disease, the only chronic disease still on the rise in western countries, affecting millions of people worldwide. For patients with end-stage liver disease (cirrhosis), the only therapeutic option is liver transplantation, a complex surgical procedure limited by complications and a shortage of donors. The company’s lead product is an autologous engineered macrophage therapy designed to treat cirrhotic patients. The company was founded in 2020 based on over a decade’s research in macrophage and liver disease by Prof. Stuart Forbes and Prof. John Campbell. Today, Resolution is a leader in developing and manufacturing macrophage cell therapy with potential applications in a wide range of life-threatening conditions. The company, backed by Syncona, has raised over $50 million to advance the lead product into clinical trials.

www.resolution-tx.com

Kevin Bruce, Chief Operating Officer

April 12 | 10:00am | Dark Horse Consulting Ballroom 

Edinburgh, Scotland

(Private)

RoslinCT is a leading cell therapy contract development and manufacturing organization (CDMO), enabling you to safely bring your autologous or allogeneic therapy to patients. We operate a fully licensed GMP manufacturing facility and have a proven track record in the delivery of cell-based products. We offer a range of integrated services from technology transfer, process, and assay development through to GMP manufacturing, storage, QP certification, and batch release of cell-based therapies for clinical trials. We also engage with leading cell and gene therapy developers providing a personalized service. At the heart of RoslinCT is a dynamic, highly experienced team that will understand your goals and will partner with you to get your therapy to market efficiently and effectively. We put quality and integrity at the heart of the business to make sure we provide you with the trust that your life-changing therapy is on the right pathway to commercialization.

www.roslinct.com

Thomas Tradler, Head of the Executive Department Business Development and Patent Management

April 13 | 12:00pm | Dark Horse Consulting Ballroom 

Leipzig, Germany

(Private)

SaxoCell is the Saxon Cell and Gene Therapy Future Cluster, a winner of the innovation competition “Clusters4Future” of the Federal Ministry of Education and Research (BMBF). Core partners of our cluster are the Fraunhofer IZI, the TU Dresden, the University of Leipzig and the Hospital Chemnitz gGmbH, collaborating closely with many further regional, national, and international research and industry partners. Our vision is to become a European lighthouse for cell and gene therapy. We will bring safe and affordable ATMPs to patients, strongly support innovation efforts of the industry, and make Saxony a home for Europe’s leading cell and gene therapy companies. The Fraunhofer Institute for Cell Therapy and Immunology IZI, as one of Saxocell`s core partners, is a leading institution in applied research and development of innovative products and technologies, having a particular focus on innovative cell and gene therapies.

www.saxocell.de

Neil McGowan, Ph.D., Associate Director, TCAT GMP

April 13 | 4:30pm | Dark Horse Consulting Ballroom 

Edinburgh, United Kingdom

(Private)

Tissues, Cells and Advanced Therapeutics (TCAT) at the Scottish National Blood Transfusion Service is an established developer and manufacturer of cell therapy products. From two GMP manufacturing facilities, SNBTS have 20 years’ experience delivering autologous and allogeneic products for FIH, Phase 1 & 2 trials, and manufacture of Master Cell Banks of hESC and iPSC lines. As an NHS establishment, TCAT is uniquely positioned to support academic and other early-stage developers in the translation of their ‘proof of concept’ stage products into GMP-compatible processes, and to manufacture these products for early-stage clinical trials. TCAT has proven expertise working with somatic cells, pluripotent stem cells and their derivatives, and genetically modified cell therapies. SNBTS TCAT has extensive in-house QC capacity, specifically developed for ATMPs, including endotoxin and sterility, cell identify and function, and stability studies. These QC services are offered as part of a CDMO package or as stand-alone services.

www.scotblood.co.uk

Philip Toleikis, Ph.D., CEO and President

April 13 | 3:45pm | BioCentriq Ballroom 

London Ontario, Canada

(NASDAQ: SVA)

Sernova is a clinical-stage biotechnology company developing therapeutic cell technologies with a goal to deliver a ‘functional cure’ for chronic diseases, including insulin-dependent diabetes, thyroid disease, and hemophilia A. Sernova has developed the Cell Pouch System™, an implantable, scalable, and retrievable medical device which forms a natural environment for long-term survival and function of immune-protected therapeutic cells. In Sernova’s T1D clinical program, the first three patients to complete the trial protocol have achieved insulin independence. A second patient cohort has now been initiated with interim results expected in H2, 2023. In 2022, Sernova and Evotec (NASDAQ: EVO) entered into a partnership to develop an off-the-shelf iPSC-based islet replacement therapy for potentially millions of patients with diabetes. Sernova has licensed a technology from the University of Miami to cloak cells, potentially eliminating the need for immunosuppressives to protect against immune system attack.

www.sernova.com

Dr. Roland Kolbeck, Ph.D., Chief Scientific Officer

April 13 | 9:45am | Dark Horse Consulting Ballroom 

Philadelphia, PA

(Private)

Spirovant is a gene therapy company located in Philadelphia’s thriving Life Sciences Corridor. Our diverse management team, researchers, and partners focus on innovative treatments for respiratory diseases. At Spirovant, we are passionate about “CURES” – collaboration, urgency, respect, empowerment, and science.

www.spirovant.com

Matthew Lakelin, Ph.D., Co-Founder and Vice President, Scientific Affairs and Product Development

April 12 | 3:45pm | Dark Horse Consulting Ballroom 

Cardiff, United Kingdom

(Private)

TrakCel is the first provider of integrated cellular orchestration solutions for the precise management, control, and tracking of cell and gene therapy products. With the largest number of live deployments supporting the broadest number of therapy classes in industry, TrakCel has built a deep understanding of the unique challenges faced by advanced therapy developers globally. OCELLOS by TrakCel is a powerful, integrated cellular orchestration solution for the precise management, control and tracking of advanced therapy supply chains, patient by patient. OCELLOS supports autologous, allogeneic, and personalized cancer vaccine therapies at all clinical and commercial stages whilst brand new OCELLOS Lite has been developed for quick, cost-effective deployment for early-stage clinical therapies. TrakCel’s cell orchestration platforms help to establish and safeguard the therapy Chain of Identity and Chain of Custody whilst generating full, reportable, electronic audit trails in real-time for each patient.

www.trakcel.com

Frederic Desdouits, Ph.D., CEO

April 12 | 4:30pm | Dark Horse Consulting Ballroom 

Bordeaux, France

(Private)

TreeFrog Therapeutics is one of the rare cell therapy biotechs that leverages biophysics to overcome critical bottlenecks of the industry, introducing new standards in terms of scalability, cell quality, transplantation efficiency, and safety/functionality of cell therapy products. Headquartered in France, with offices and labs in the U.S. and Japan, TreeFrog is advancing a pipeline of therapeutic candidates in regenerative medicine and immuno-oncology based on a disruptive cell culture platform, C-Stem™. Founded to make cell therapies accessible to large patient populations, the company is developing an iPS-derived cell therapy in Parkinson’s disease with a best-in-class profile (Phase I in 2025), building therapeutic partnerships in NK cell therapies (including Umoja Biopharma), and aims at closing comprehensive platform deals with industry leaders within the next two years.

www.treefrog.fr

Barbara Sanders, Ph.D., Chief Technology Officer

April 13 | 3:15pm | Dark Horse Consulting Ballroom 

Amsterdam, Netherlands

(Private)

VectorY Therapeutics is a preclinical biotech company that develops vectorized antibody treatments for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), Huntington’s and Parkinson’s disease. Our lead program, VTx-001 targeting oxidized phospholipids (OxPC) in ALS, is currently in preclinical development. Our platform consists of engineered AAV vectors, transformative antibodies (VecTabs), antibody/degron fusion proteins (VecTrons), and proprietary manufacturing processes. Our technology enables long-lasting antibody treatment of the CNS after a single administration that potentially provides much needed disease modifying treatments for neurodegenerative diseases with a high unmet medical need.

www.vectorytx.com

Petter Bjorquist, Ph.D., CEO

April 13 | 3:30pm | Dark Horse Consulting Ballroom 

Gothenburg, Sweden

(Private)

VERIGRAFT is a Swedish biotechnology company run by experienced entrepreneurs and mastering a unique, breakthrough technology in the field of advanced therapies and regenerative medicine. We make transplantation possible without the severe risks of immunosuppression, and develop advanced therapies and tissue engineered products that will be able to help millions of patients with serious diseases. Our first product, the Personalized Tissue Engineered Vein (P-TEV) is a human vein segment graft for use in transplantation to replace a defective or missing part of a patient’s vein. A P-TEV with functioning valves is implanted to replace a non-functioning venous valve in the femoral vein of a patient suffering from severe chronic venous insufficiency (CVI). The first-in-man clinical trial is ongoing, and results are very positive.

www.verigraft.com

Robert Ang, President and CEO

April 12 | 11:30am | BioCentriq Ballroom 

Cambridge, MA

(NASDAQ: VOR)

Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant.

www.vorbio.com

Evy Lundgren-Akerlund, Ph.D., CEO

April 13 | 11:30am | BioCentriq Ballroom 

Lund, Sweden

(NASDAQ: XINT.ST)

Xintela is a clinical-stage biopharma company developing allogeneic MSC-based therapies. Xintela’s proprietary product platform XSTEM® consists of homogenous integrin α10β1-selected adipose tissue derived MSCs with superior potency and consistency compared to other MSC technologies. Xintela’s first therapeutic focus is osteoarthritis (OA) and difficult-to-heal venous leg ulcers (VLU). Preclinical studies in large animals, support disease modifying effects in OA and VLU and for treatment of Acute Respiratory Distress Syndrome (ARDS). XSTEM is manufactured in Xintela’s own GMP facility. A First-in-Human study (Phase I/IIa, dose escalation) with XSTEM is ongoing in knee OA patients (KL grade II-III). XSTEM has also entered into Phase I/IIa clinical study for the treatment of difficult-to-heal VLU. During 2023, we expect safety and efficacy readouts from the VLU study as well as safety from all dose levels and early efficacy signals from the OA study.

www.xintela.se